These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32371100)

  • 1. Synthesis and pharmacological evaluation of bivalent tethered ligands to target the mGlu
    Fulton MG; Loch MT; Rodriguez AL; Lin X; Javitch JA; Conn PJ; Niswender CM; Lindsley CW
    Bioorg Med Chem Lett; 2020 Jul; 30(13):127212. PubMed ID: 32371100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers.
    Niswender CM; Jones CK; Lin X; Bubser M; Thompson Gray A; Blobaum AL; Engers DW; Rodriguez AL; Loch MT; Daniels JS; Lindsley CW; Hopkins CR; Javitch JA; Conn PJ
    ACS Chem Neurosci; 2016 Sep; 7(9):1201-11. PubMed ID: 27441572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2.
    Lundström L; Bissantz C; Beck J; Dellenbach M; Woltering TJ; Wichmann J; Gatti S
    Neuropharmacology; 2016 Dec; 111():253-265. PubMed ID: 27590915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reprint of Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2.
    Lundström L; Bissantz C; Beck J; Dellenbach M; Woltering TJ; Wichmann J; Gatti S
    Neuropharmacology; 2017 Mar; 115():115-127. PubMed ID: 28216000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence.
    Dhanya RP; Sheffler DJ; Dahl R; Davis M; Lee PS; Yang L; Nickols HH; Cho HP; Smith LH; D'Souza MS; Conn PJ; Der-Avakian A; Markou A; Cosford ND
    J Med Chem; 2014 May; 57(10):4154-72. PubMed ID: 24735492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges in the Discovery and Optimization of mGlu
    Fulton MG; Loch MT; Cuoco CA; Rodriguez AL; Days E; Vinson PN; Kozek KA; Weaver CD; Blobaum AL; Conn PJ; Niswender CM; Lindsley CW
    Lett Drug Des Discov; 2019 Dec; 16(12):1387-1394. PubMed ID: 32201485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.
    Maksymetz J; Moran SP; Conn PJ
    Mol Brain; 2017 Apr; 10(1):15. PubMed ID: 28446243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential Pharmacology and Binding of mGlu
    O'Brien DE; Shaw DM; Cho HP; Cross AJ; Wesolowski SS; Felts AS; Bergare J; Elmore CS; Lindsley CW; Niswender CM; Conn PJ
    Mol Pharmacol; 2018 May; 93(5):526-540. PubMed ID: 29545267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and preliminary studies of
    Zhang X; Zhang Y; Chen Z; Shao T; Van R; Kumata K; Deng X; Fu H; Yamasaki T; Rong J; Hu K; Hatori A; Xie L; Yu Q; Ye W; Xu H; Sheffler DJ; Cosford NDP; Shao Y; Tang P; Wang L; Zhang MR; Liang SH
    Theranostics; 2020; 10(24):11178-11196. PubMed ID: 33042277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis.
    Benneyworth MA; Xiang Z; Smith RL; Garcia EE; Conn PJ; Sanders-Bush E
    Mol Pharmacol; 2007 Aug; 72(2):477-84. PubMed ID: 17526600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR.
    Sanger H; Hanna L; Colvin EM; Grubisha O; Ursu D; Heinz BA; Findlay JD; Vivier RG; Sher E; Lodge D; Monn JA; Broad LM
    Neuropharmacology; 2013 Mar; 66():264-73. PubMed ID: 22659090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allosteric control of an asymmetric transduction in a G protein-coupled receptor heterodimer.
    Liu J; Zhang Z; Moreno-Delgado D; Dalton JA; Rovira X; Trapero A; Goudet C; Llebaria A; Giraldo J; Yuan Q; Rondard P; Huang S; Liu J; Pin JP
    Elife; 2017 Aug; 6():. PubMed ID: 28829739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of dual positive allosteric modulators (PAMs) of the metabotropic glutamate 2 receptor and CysLT1 antagonists for treating migraine headache.
    Blanco MJ; Benesh DR; Knobelsdorf JA; Khilevich A; Cortez GS; Mokube F; Aicher TD; Groendyke TM; Marmsater FP; Tang TP; Johnson KW; Clemens-Smith A; Muhlhauser MA; Swanson S; Catlow J; Emkey R; Johnson MP; Schkeryantz JM
    Bioorg Med Chem Lett; 2017 Jan; 27(2):323-328. PubMed ID: 27908761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurophysiologic and antipsychotic profiles of TASP0433864, a novel positive allosteric modulator of metabotropic glutamate 2 receptor.
    Hiyoshi T; Marumo T; Hikichi H; Tomishima Y; Urabe H; Tamita T; Iida I; Yasuhara A; Karasawa J; Chaki S
    J Pharmacol Exp Ther; 2014 Dec; 351(3):642-53. PubMed ID: 25277141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive allosteric modulators (PAMs) of the group II metabotropic glutamate receptors: Design, synthesis, and evaluation as ex-vivo tool compounds.
    Yamada Y; Gilliland K; Xiang Z; Haymer D; Crocker KE; Loch MT; Schulte ML; Rodriguez AL; Niswender CM; Jeffrey Conn P; Lindsley CW; Melancon BJ
    Bioorg Med Chem Lett; 2021 Oct; 50():128342. PubMed ID: 34461178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNS.
    Yin S; Noetzel MJ; Johnson KA; Zamorano R; Jalan-Sakrikar N; Gregory KJ; Conn PJ; Niswender CM
    J Neurosci; 2014 Jan; 34(1):79-94. PubMed ID: 24381270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships.
    Gregory KJ; Noetzel MJ; Rook JM; Vinson PN; Stauffer SR; Rodriguez AL; Emmitte KA; Zhou Y; Chun AC; Felts AS; Chauder BA; Lindsley CW; Niswender CM; Conn PJ
    Mol Pharmacol; 2012 Nov; 82(5):860-75. PubMed ID: 22863693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of 5-aryl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones as positive allosteric modulators of metabotropic glutamate subtype-2 (mGlu2) receptors with efficacy in a preclinical model of psychosis.
    Layton ME; Reif AJ; Hartingh TJ; Rodzinak K; Dudkin V; Wang C; Arrington K; Kelly MJ; Garbaccio RM; O'Brien JA; Magliaro BC; Uslaner JM; Huszar SL; Fillgrove KL; Tang C; Kuo Y; Jacobson MA
    Bioorg Med Chem Lett; 2016 Feb; 26(4):1260-4. PubMed ID: 26810316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Synthesis, and Pharmacological Characterization of Heterobivalent Ligands for the Putative 5-HT
    Poulie CBM; Liu N; Jensen AA; Bunch L
    J Med Chem; 2020 Sep; 63(17):9928-9949. PubMed ID: 32815361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allosteric modulators enhance agonist efficacy by increasing the residence time of a GPCR in the active state.
    Cao AM; Quast RB; Fatemi F; Rondard P; Pin JP; Margeat E
    Nat Commun; 2021 Sep; 12(1):5426. PubMed ID: 34521824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.